Lumexa Imaging Holdings Inc (NASDAQ:LMRI), a major national provider of outpatient imaging services, reported its preliminary fourth quarter and full-year 2025 results before the market opened on March 26, 2026. The report presented a complex picture of operational growth overshadowed by significant bottom-line losses, leading to a mixed market reception in early trading.
Earnings and Revenue Versus Estimates
The company's financial performance for the quarter and full year deviated sharply from analyst expectations, particularly on profitability. While revenue showed steady growth, earnings per share (EPS) fell deeply into negative territory.
For the fourth quarter of 2025:
- Reported Revenue: $267.7 million, representing a 7.9% year-over-year increase.
- Reported EPS (GAAP): A net loss of $0.38 per share.
- Analyst Expectations: The consensus estimate was for revenue of approximately $266.4 million and a profit of $0.07 per share (Non-GAAP).
For the full year 2025:
- Reported Revenue: $1.023 billion, up 7.8% from 2024.
- Reported EPS (GAAP): A net loss of $0.66 per share.
- Analyst Expectations: Analysts were anticipating a full-year Non-GAAP EPS profit of $0.07.
The substantial miss on EPS, turning an expected profit into a sizable loss, is the most glaring discrepancy from the report. The company attributes a portion of the net loss to a $13.5 million loss on extinguishment of debt recorded in Q4.
Market Reaction and Price Action
The market's initial reaction to the earnings release has been negative, reflecting investor concern over the profitability shortfall despite the revenue growth. In the period leading up to the announcement, the stock experienced significant downward pressure, which has continued post-release.
- The stock has declined approximately 11.7% over the past week.
- It is down about 24.8% over the last month.
This pre- and post-earnings sell-off suggests that investors are prioritizing the earnings miss and ongoing net losses over the company's top-line expansion and operational improvements. The reiteration of 2026 guidance provided some stability, but was not enough to counteract the negative sentiment from the 2025 results.
Key Highlights from the Press Release
Beyond the headline revenue and earnings figures, Lumexa's report emphasized strong operational momentum and significant progress on its balance sheet.
Operational Strength:
- Volume Growth: Consolidated advanced imaging volumes (MRI and CT) grew 12.7% year-over-year in Q4. For the full year, system-wide procedures reached approximately 4 million.
- Expansion: The company added ten new imaging facilities in 2025, including nine new "de novo" centers, marking a record year for expansion.
- Profitability Metric: Adjusted EBITDA, a non-GAAP measure of operational profitability, showed robust growth. Full-year Adjusted EBITDA increased 14.6% to $230.2 million, with a margin of 22.5%.
Financial Health Improvement:
- Debt Reduction: A key achievement highlighted was a two-turn reduction in leverage, from 5.5x to 3.5x. Management stated this will result in over $50 million in annual cash interest savings.
- Strengthened Balance Sheet: The company ended the year with $58.8 million in cash and cash equivalents, more than double the prior year's balance.
2026 Outlook Versus Analyst Forecasts
Lumexa reiterated its full-year 2026 guidance, providing a benchmark against current analyst projections.
- Company 2026 Guidance:
- Consolidated Revenue: $1.045 to $1.097 billion.
- Adjusted EBITDA: $234 to $242 million.
- Adjusted EPS: $0.71 to $0.77 per share.
- Analyst Estimates for 2026:
- Sales: Approximately $1.087 billion.
- Revenue: Approximately $800.8 million (note: this appears to be a discrepancy in data labeling; the sales figure is the more direct comparison to company revenue guidance).
The midpoint of the company's revenue guidance ($1.071 billion) is slightly below the current analyst sales consensus. More notably, the company's Adjusted EPS guidance of $0.71-$0.77 provides its first formal projection of profitability on an adjusted basis for the coming year. The company noted that its 2026 Adjusted EBITDA includes approximately $7 million in new public company costs not incurred in 2025.
For a detailed look at historical earnings and future analyst projections, you can review the earnings history and estimates page for LMRI.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.